アムリテリマブ喘息臨床試験の治療期間を完了した中等症から重症喘息の成人患者における皮下投与アムリテリマブの長期安全性および有効性評価

基本情報

NCT ID

NCT06033833

ステータス

実施中（募集終了）

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

335

治験依頼者名

Sanofi

概要

This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enrolled and completed the treatment period of the parent study. The study duration will be up to 156 weeks. The treatment duration will be up to 144 weeks. The number of visits will be 18.

対象疾患

介入

依頼者（Sponsor）